Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy
Annals of Internal MedicinePublished 19 September 2000
Sophie Grabar, Vincent Le Moing, Cécile Goujard, Catherine Leport, Michel D. Kazatchkine, Dominique Costagliola
Citations415
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Clinical outcomes are reported in a large cohort of patients in France 24 months after initiation of triple therapy that contained protease inhibitors, according to virologic and immunologic response at 6 months, and the long-term prognosis of patients exhibiting such discordant responses remains unknown.
Abstract
BACKGROUND: The prognostic value of discordant immunologic (CD4 cell increase) and virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not known. OBJECTIVE: To study the relation between clinical outcome of HIV-infected patients receiving highly active antiretroviral therapy (HAART) and early immunologic and virologic responses to such therapy. DESIGN: Prospective cohort study. SETTING: 68 hospitals in France. PATIENTS: 2236 protease inhibitor-naive patients. INTERVENTION: Initiation of HAART with one protease inhibitor and two nucleoside analogues between July 1996 and March 1997. MEASUREMENTS: Immunologic and virologic response at 6 months. Multivariate Cox models were used to assess the relation between these responses and progression to a new AIDS-defining event or death. RESULTS: On the basis of 6-month immunologic and virologic responses, patients were classified into four groups: complete response (47.5%), complete nonresponse (16.2%), immunologic response only (19.0%), and virologic response only (17.3%). After month 6 and within a median of 18 months, 69 patients died and 123 experienced a new AIDS-defining event. After adjustment, complete nonresponders and those with only a virologic response had significantly higher risks for clinical progression at 6 months (relative risk, 3.38 [95% CI, 2.28 to 5.02] and 1.98 [CI, 1.26 to 3.10], respectively) than complete responders. The difference between complete responders and those with only an immunologic response at 6 months was weaker and nonsignificant (relative risk, 1.55 [CI, 0.96 to 2.50]). CONCLUSIONS: Immunologic response after 6 months of HAART indicates a favorable clinical outcome in HIV-infected patients regardless of virologic response. This suggests that both immunologic and virologic markers should be used in clinical practice to evaluate treatment response.
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineDeclining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
9,465 Citations1998Frank J. Palella, Kathleen M. Delaney +6 more
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Clinical Infectious Diseases1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
4,356 Citations1993K. G. Castro, Jill Ward +5 more
The classification system for HIV infection is revised to emphasize the clinical importance of the CD4+ T-lymphocyte count in the categorization of HIV-related clinical conditions and the AIDS surveillance case definition is expanded.
SciencePrognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
2,705 Citations1996John W. Mellors, Charles R. Rinaldo +4 more
Plasma viral load was a better predictor of progression to AIDS and death than was the number of CD4+ T cells, and the risk of acquired immunodeficiency syndrome (AIDS) and death in study subjects was directly related to plasma viral load at study entry.
Annals of Internal MedicinePlasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
2,085 Citations1997John W. Mellors, Alvaro Munoz +10 more
This study compared the prognostic value of plasma viral load with that of clinical, serologic, and cellular markers in a large cohort of HIV-infected men and incorporated the two most predictive markers-plasma viral load and CD4+ lymphocyte count-into a regression tree that is useful for assessing the prognosis of individual patients.
The LancetChanging patterns of mortality across Europe in patients infected with HIV-1
1,284 Citations1998Amanda Mocroft, Stefano Vella +9 more
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
PubMedSurveillance for dracunculiasis, 1981-1991.
1,111 Citations1992Hopkins Dr, Ernesto Ruiz‐Tiben
Methods for conducting surveillance of dracunculiasis and other important diseases must continue to be developed and improved as countries now believed to be free of dracanculiasis prepare to apply to WHO for certification of elimination.
JAMAAntiretroviral Therapy in Adults
1,034 Citations2000Charles C. J. Carpenter, David A. Cooper +16 more
The LancetClinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
933 Citations1999Bruno Ledergerber, Matthias Egger +10 more
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
The LancetLong-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
554 Citations1998Li Ts, Roland Tubiana +4 more
HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients, and this recovery depends not on baseline values but on the amplitude and duration of viral-load reduction and the increase of memoryCD4 T cells.
PubMedAIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
481 Citations1999Bruno Ledergerber, Matthias Egger +12 more
The data indicate that the risk of developing an OI for a person receiving potent antiretroviral therapy is highest during the initial months of therapy, and baseline CD4 cell count and immunologic and virologic response to treatment were strong predictors of disease progression in patients receiving potent therapy.
The LancetCD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
360 Citations1998Daniel E. Kaufmann, Giuseppe Pantaleo +2 more
Annals of Internal MedicineMonitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response
282 Citations1997Michael D. Hughes, Victoria A. Johnson +10 more
Annals of Internal MedicineChanges in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure
262 Citations1997William A. O’Brien, Pamela M. Hartigan +3 more
How changes in plasma HIV RNA levels and CD4+ lymphocyte count correlate with progression to AIDS is evaluated and the usefulness of these measures in assessing antiretroviral drug failure during the course of therapy is evaluated.
AIDSThe duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
224 Citations1998Dale J. Kempf, Richard A. Rode +9 more
Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy and strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response should be investigated.
AIDSDiscrepant responses to triple combination antiretroviral therapy in advanced HIV disease
223 Citations1998Christophe Piketty, Philippe Castiel +10 more
Observations of discrepant immunological and virological responses to treatment raise the issue of the significance of persistent elevated levels of plasma HIV RNA and of the relevance of measurements of plasma viral load for assessing the efficacy of antiretroviral therapy in patients whose CD4 cell counts increase despite the absence of significant decrease in plasma HIV viral load.
JAMARecovery of the Immune System With Antiretroviral Therapy
221 Citations1998William G. Powderly, Alan Landay +1 more
Potent antiretroviral therapy has become the standard of care for people with HIV infection, and its use has led to significant reductions in the incidence of the acquired immunodeficiency syndrome (AIDS) and in mortality from HIV infection.
The LancetDiscontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
185 Citations1999M. M. E. Schneider, Jan C.C. Borleffs +3 more
The preliminary results of this study indicate that PCP prophylaxis can be stopped safely in HIV-1-infected patients whose CD4 cell counts have increased above 200 cells/microL after treatment with HAART.
AIDSFactors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
177 Citations2000Sophie Grabar, Christian Pradier +9 more
In this study with large samples of patients, the use of saquinavir-hgc was associated with higher risk of virological failure at 12 months than were ritonavir and indinavir; no differences between protease inhibitors were found for clinical progression.
BloodHuman Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis In Vitro and In Vivo
168 Citations1999Elaine M. Sloand, Princy Kumar +4 more
Protease inhibitors appear to decrease CD4(+) T-cell ICE expression and apoptosis before they affect Fas-R expression in HIV-infected patients.
The LancetHIV-1 replication in patients with undetectable plasma virus receiving HAART
140 Citations1999Ven Natarajan, Marjorie Bosche +4 more
AIDSThe relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection
85 Citations1998Alessandro Cozzi‐Lepri, Terese L. Katzenstein +5 more
It appears that the HIV RNA level has a relatively weak association with risk of death in patients with advanced HIV infection and that the CD4 lymphocyte count is probably more useful in assessing prognosis.
New England Journal of MedicineImprovement in CD4+ Cell Counts despite Persistently Detectable HIV Load
80 Citations1998Stuart M. Levitz
A major goal of antiretroviral therapy for human immunodeficiency virus (HIV) infection should be to keep the viral load undetectable or at least suppressed as fully as possible.
Journal of VirologyGenotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy
79 Citations1998Peter Eastman, John E. Mittler +9 more
The concomitant acquisition of an L63P/A mutation with the V82A/F mutation at the time when plasma RNA levels rebounded suggests a role for the L63p/A mutations in improving the fitness of the V 82A/f mutation.
AIDSChanges in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment
69 Citations1998Geneviève Chêne, Christine Binquet +7 more
The results show, at least indirectly, how protease inhibitors might produce clinical stabilization, and may be due to improved functionality of CD4+ cells in patients started on protease inhibitor therapy.
AIDSCD4 cell counts at the third month of HAART may predict clinical failure
52 Citations1999Antonella d‚Arminio Monforte, Valeria Testori +13 more
The 3-month immunological response is a reliable predictor of long-term clinical outcome in patients receiving their first highly active antiretroviral therapy (HAART) regimen.
The Journal of Infectious DiseasesHigh Levels of Drug‐Resistant Human Immunodeficiency Virus Variants in Patients Exhibiting Increasing CD4<sup>+</sup>T Cell Counts Despite Virologic Failure of Protease Inhibitor–Containing Antiretroviral Combination Therapy
47 Citations2000Laurent Bélec, Christophe Piketty +6 more
Analysis of genotypic resistance and plasma human immunodeficiency virus RNA level as surrogate markers in patients receiving HAART indicates that many patients have prolonged immunologic benefits, despite the development of virologic failure and protease inhibitor mutations.
Annals of Internal Medicine1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus
19 Citations1999USPHS/IDSA Prevention of Opportunistic Infections Working Group
JAIDS Journal of Acquired Immune Deficiency SyndromesDefinition of Virologic Response and the Type of Assay Used for Quantification of Viral Load May Influence the Proportion of Responders to Antiretroviral Therapy
7 Citations2000Vincent Le Moing, Geneviève Chêne +5 more